Real-World data on ovarian cancer treatments collected in russia

NCT ID NCT05918042

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how doctors in Russia treat a specific type of ovarian cancer called HRD-positive. Researchers collected information from 414 patients to understand what treatments they received and how they fared. The goal was to describe real-world practice, not to test a new drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Research Site

Arkhangelsk, Russia
Research Site

Barnaul, Russia
Research Site

Chelyabinsk, Russia
Research Site

Grozny, Russia
Research Site

Irkutsk, Russia
Research Site

Izhevsk, Russia
Research Site

Kaliningrad, Russia
Research Site

Kaluga, Russia
Research Site

Krasnodar, Russia
Research Site

Krasnoyarsk, Russia
Research Site

Lyubertcy, Russia
Research Site

Moscow, Russia
Research Site

N.Novgorod, Russia
Research Site

Nal'chik, Russia
Research Site

Novosibirsk, Russia
Research Site

Omsk, Russia
Research Site

Saint Petersburg, Russia
Research Site

Saratov, Russia
Research Site

Sochi, Russia
Research Site

Tomsk, Russia
Research Site

Ufa, Russia
Research Site

Vladivostok, Russia
Research Site

Yakutiya, Russia
Research Site

Yaroslavl, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.